Run by

The LEAD Group Inc
The Lead Education and Abatement Design Group
Working to eliminate lead poisoning globally and to protect the
environment from lead in all its uses: past, current and new uses
ABN 25 819 463 114
Australians! Take action
today. Is lead harming
you & your kids? Buy low
cost, NATA accredited
laboratory lead test kits
here. Sample your dust,
soil, water, paint, toys,
jewellery, ceramics
what's new 

Water Lead test Kits

Proceeds from our DIY Home Lead Assessment kit sales go towards the
Keeping Australian Lead Out of Leaded Petrol Initiative.

Search this site
Search tips 
What's New

About Us
bell system lead poisoning
Contact Us
Council Lead Project
Library-Fact Sheets
Home Page
Media Releases
Referral Lists
Site Map
Slide Shows-Films
Useful Links

Visitor Number


QUESTION: Is chelation of significance for people suffering from dilated cardiomyopathy? - 09 Mar 2007 Victoria, Australia

I am 77 yoa, and 2 years ago diagnosed with Dilated Cardiomyopathy.

I ask is Chelation of any significance for me? Any information you can provide will be of great use, as I am currently the National Membership Secretary of the Cardiomyopathy Association of Australia.

Looking forward to any info you can supply,

Yours Faithfully, Peter

Answer: 09 Mar 2007

1. NULL,of antimony and greater than 22,000 times the normal levels of mercury in biopsied myocardial cells. No such increase in toxicant metals was found in controls. The researchers hypothesized that the metals may adversely affect mitochondrial activity and myocardial metabolism and worsen cellular function. Could it be that they have discovered an idiopathic, organ-specific metal toxicity that leads to cardiomyopathy? Could the physician have had the same etiology for his cardiomyopathy, which may have responded to the detoxification of the toxicant metals? We may never know, but logic dictates that it is possible. The toxic metals may have been removed with chelation therapy, causing the patient's clinical symptoms to improve. These are the types of clinical observations that can alter the course of current medical treatments.

2. Andrea Frustaci, MD; Nicola Magnavita, MD; Cristina Chimenti, MD; Marina Caldarulo, MD; Enrico Sabbioni, PhD; Romano Pietra, PhD; Carlo Cellini, MD; Gian Federico Possati, MD; Attilio Maseri, MD. Marked elevation of myocardial trace elements in idiopathic dilated cardiomyopathy compared with secondary cardiac dysfunction. J Am Coll Cardiol. 1999;33(6):1578-1583.

3. [This reference does not itself mention chelation but the following extract explains why chelation has been associated with dilated cardiomyopathy as in the two references above.] "Marked Elevation of Myocardial Trace Elements in Idiopathic Dilated Cardiomyopathy Compared With Secondary Cardiac Dysfunction" by Andrea Frustaci, Nicola Magnavita, Cristina Chimenti, Marina Caldarulo, Enrico Sabbioni, Romano Pietra, Carlo Cellini, Gian Federico Possati & Attilio Maseri, in Journal of the American College of Cardiology Vol. 33, No. 6, 1999.

RESULTS A large increase (.10,000 times for mercury and antimony) of TE concentration has been observed in myocardial but not in muscular samples in all pts with IDCM. Patients with secondary cardiac dysfunction had mild increase (#5 times) of myocardial TE and normal muscular TE. In particular, in pts with IDCM mean mercury concentration was 22,000 times (178,400 ng/g vs. 8 ng/g), antimony 12,000 times (19,260 ng/g vs. 1.5 ng/g), gold 11 times (26 ng/g vs. 2.3 ng/g), chromium 13 times (2,300 ng/g vs. 177 ng/g) and cobalt 4 times (86,5 ng/g vs. 20 ng/g) higher than in control subjects. CONCLUSIONS A large, significant increase of myocardial TE is present in IDCM but not in secondary cardiac dysfunction. The increased concentration of TE in pts with IDCM may adversely affect mitochondrial activity and myocardial metabolism and worsen cellular function. (J Am Coll Cardiol 1999;33:1578-83) © 1999 by the American College of Cardiology

4. The cardiac changes in thalassemia major: their assessment by Doppler echocardiography [ABSTRACT ONLY] [Full article is in Italian] by Favilli S, De Simone L, Mori F, Pollini I, Cecchi F, Zuppiroli A, Manetti A in G Ital Cardiol. 1993 Dec;23(12):1195-200.

Dilated cardiomyopathy with impaired left ventricular function is the most common cause of death in patients (pts) with Thalassemia Major (TM) undergoing multiple transfusions. To assess the cardiac status in a young population with TM, 25 pts (mean age 15.8 +/- 5.7 years) and 25 controls (sex and age matched), underwent clinical, echocardiographic and Doppler evaluation. Thirteen pts who received a correct chelation therapy had serum Ferritin (F) below, and nine pts up to 1300 ng/ml. Three out of 9 pts with F > 1300 ng/ml were symptomatic for heart failure, and echocardiography showed a dilated cardiomyopathy.... Our study suggests that a correct chelation therapy may protect pts with TM from early development of a dilated cardiomyopathy.

I hope this helps Yours Sincerely Elizabeth O’Brien

About Us | bell system lead poisoning | Contact Us | Council LEAD Project | egroups | Library - Fact Sheets | Home Page | Media Releases
| Q & A | Referral lists | Reports | Site Map | Slide Shows - Films | Subscription | Useful Links |  Search this Site
Privacy Policy | Disclaimer

Last Updated 01 January 2013
Copyright © The LEAD Group Inc. 1991- 2013
PO Box 161 Summer Hill NSW 2130 Australia
Phone: +61 2 9716 0014